{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T17:11:29Z","timestamp":1794244289689,"version":"4.9.0"},"reference-count":36,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","dldjournalonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Digestive and Liver Disease"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/j.dld.2024.07.018","type":"journal-article","created":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T18:40:27Z","timestamp":1722537627000},"page":"1828-1838","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["Small molecules for inflammatory bowel disease and the risk of infection and malignancy: A systematic review and meta-Analysis"],"prefix":"10.1016","volume":"56","author":[{"given":"LiXue","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiao","family":"Mei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.dld.2024.07.018_bib0001","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1016\/S0140-6736(16)31711-1","article-title":"Crohn's disease","volume":"389","author":"Torres","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.dld.2024.07.018_bib0002","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1016\/S0140-6736(16)32126-2","article-title":"Ulcerative colitis","volume":"389","author":"Ungaro","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.dld.2024.07.018_bib0003","doi-asserted-by":"crossref","first-page":"5024","DOI":"10.3748\/wjg.v16.i40.5024","article-title":"Health related quality of life in inflammatory bowel disease: the impact of surgical therapy","volume":"16","author":"Umanskiy","year":"2010","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.dld.2024.07.018_bib0004","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/j.crohns.2013.01.010","article-title":"The burden of inflammatory bowel disease in Europe","volume":"7","author":"Burisch","year":"2013","journal-title":"J Crohn's Colitis"},{"key":"10.1016\/j.dld.2024.07.018_bib0005","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1007\/s40265-019-01169-y","article-title":"Innovations in Oral Therapies for Inflammatory Bowel Disease","volume":"79","author":"Ma","year":"2019","journal-title":"DrugsDrugs"},{"key":"10.1016\/j.dld.2024.07.018_bib0006","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1056\/NEJMct1209614","article-title":"Tumor Necrosis Factor Inhibitors for Inflammatory Bowel Disease","volume":"369","author":"Nielsen","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.dld.2024.07.018_bib0007","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.crohns.2010.04.004","article-title":"Report of the ECCO pathogenesis workshop on anti-TNF therapy failures in inflammatory bowel diseases: definitions, frequency and pharmacological aspects","volume":"4","author":"Allez","year":"2010","journal-title":"J Crohn's Colitis"},{"key":"10.1016\/j.dld.2024.07.018_bib0008","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1136\/gutjnl-2016-312912","article-title":"Next generation of small molecules in inflammatory bowel disease","volume":"66","author":"Olivera","year":"2017","journal-title":"GutGut"},{"key":"10.1016\/j.dld.2024.07.018_bib0009","first-page":"jjad100","article-title":"Efficacy and safety of advanced oral small molecules for inflammatory bowel disease: systematic review and meta-analysis","author":"Solitano","year":"2023","journal-title":"J Crohn's Colitis"},{"key":"10.1016\/j.dld.2024.07.018_bib0010","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1007\/s40265-023-01840-5","article-title":"Safety of Janus kinase inhibitors in inflammatory bowel diseases","volume":"83","author":"N\u00fa\u00f1ez","year":"2023","journal-title":"Drugs"},{"key":"10.1016\/j.dld.2024.07.018_bib0011","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijsu.2021.105906","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"88","author":"Page","year":"2021","journal-title":"Int J Surg"},{"key":"10.1016\/j.dld.2024.07.018_bib0012","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/2046-4053-4-1","article-title":"Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement","volume":"4","author":"Group","year":"2015","journal-title":"Syst Rev"},{"key":"10.1016\/j.dld.2024.07.018_bib0013","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration's tool for assessing risk of bias in randomized trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"key":"10.1016\/j.dld.2024.07.018_bib0014","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"7","author":"DerSimonian","year":"1986","journal-title":"Control Clin Trials"},{"key":"10.1016\/j.dld.2024.07.018_bib0015","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ"},{"key":"10.1016\/j.dld.2024.07.018_bib0016","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.2307\/2533446","article-title":"Operating characteristics of a rank correlation test for publication bias","volume":"50","author":"Begg","year":"1994","journal-title":"Biometrics"},{"key":"10.1016\/j.dld.2024.07.018_bib0017","doi-asserted-by":"crossref","first-page":"101","DOI":"10.2307\/3001666","article-title":"The combination of estimates from different experiments","volume":"10","author":"Cochran","year":"1954","journal-title":"Biometrics"},{"key":"10.1016\/j.dld.2024.07.018_bib0018","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"10.1016\/j.dld.2024.07.018_bib0019","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1002\/sim.1186","article-title":"Quantifying heterogeneity in a meta-analysis","volume":"21","author":"Higgins","year":"2002","journal-title":"Stat Med"},{"key":"10.1016\/j.dld.2024.07.018_bib0020","unstructured":"Sands B.E., Sandborn W.J., Feagan B.G., et al. Peficitinib, an Oral Janus Kinase inhibitor, in moderate-to-severe ulcerative colitis: results from a randomized, Phase 2 Study n.d."},{"key":"10.1016\/j.dld.2024.07.018_bib0021","doi-asserted-by":"crossref","unstructured":"Sandborn W.J. Efficacy of Upadacitinib in a randomized trial of patients with active ulcerative colitis 2020;158.","DOI":"10.1053\/j.gastro.2020.02.030"},{"key":"10.1016\/j.dld.2024.07.018_bib0022","unstructured":"Pan\u00e9s J., Sandborn W.J., Schreiber S., et al. Tofacitinib for induction and maintenance therapy of Crohn's disease: results of two phase IIb randomized placebo-controlled trials. Inflammatory Bowel Disease n.d."},{"key":"10.1016\/j.dld.2024.07.018_bib0023","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/S0140-6736(16)32537-5","article-title":"Clinical remission in patients with moderate-to-severe Crohn's disease treated with filgotinib (the FITZROY study): results from a phase 2, double-blind, randomized, placebo-controlled trial","volume":"389","author":"Vermeire","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.dld.2024.07.018_bib0024","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1016\/S0140-6736(23)00061-2","article-title":"Etrasimod as induction and maintenance therapy for ulcerative colitis (ELEVATE): two randomized, double-blind, placebo-controlled, phase 3 studies","volume":"401","author":"Sandborn","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.dld.2024.07.018_bib0025","doi-asserted-by":"crossref","first-page":"2372","DOI":"10.1016\/S0140-6736(21)00666-8","article-title":"Filgotinib as induction and maintenance therapy for ulcerative colitis (SELECTION): a phase 2b\/3 double-blind, randomized, placebo-controlled trial","volume":"397","author":"Feagan","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.dld.2024.07.018_bib0026","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1016\/S0140-6736(22)00581-5","article-title":"Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, multicentre, double-blind, randomized trials","volume":"399","author":"Danese","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.dld.2024.07.018_bib0027","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1056\/NEJMoa1513248","article-title":"Ozanimod induction and maintenance treatment for ulcerative colitis","volume":"374","author":"Sandborn","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.dld.2024.07.018_bib0028","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1056\/NEJMoa1606910","article-title":"Tofacitinib as induction and maintenance therapy for ulcerative colitis","volume":"376","author":"Sandborn","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.dld.2024.07.018_bib0029","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1056\/NEJMoa1112168","article-title":"Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis","volume":"367","author":"Sandborn","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.dld.2024.07.018_bib0030","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1056\/NEJMoa2033617","article-title":"Ozanimod as induction and maintenance therapy for ulcerative colitis","volume":"385","author":"Sandborn","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.dld.2024.07.018_bib0031","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1056\/NEJMoa2212728","article-title":"Upadacitinib induction and maintenance therapy for Crohn's disease","volume":"388","author":"Loftus","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.dld.2024.07.018_bib0032","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1053\/j.gastro.2019.10.035","article-title":"Efficacy and safety of Etrasimod in a Phase 2 randomized trial of patients with ulcerative colitis","volume":"158","author":"Sandborn","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1016\/j.dld.2024.07.018_bib0033","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1053\/j.gastro.2020.01.047","article-title":"Efficacy and safety of upadacitinib in a randomized trial of patients with Crohn's disease","volume":"158","author":"Sandborn","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1016\/j.dld.2024.07.018_bib0034","doi-asserted-by":"crossref","first-page":"2380","DOI":"10.1136\/gutjnl-2022-327025","article-title":"The future of drug development for inflammatory bowel disease: the need to ACT (advanced combination treatment)","volume":"71","author":"Danese","year":"2022","journal-title":"Gut"},{"key":"10.1016\/j.dld.2024.07.018_bib0035","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/apt.15297","article-title":"Systematic review with meta-analysis: efficacy and safety of oral Janus kinase inhibitors for inflammatory bowel disease","volume":"50","author":"Ma","year":"2019","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.dld.2024.07.018_bib0036","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1136\/ard-2023-224049","article-title":"JAK inhibitors and the risk of malignancy: a meta-analysis across disease indications","volume":"82","author":"Russell","year":"2023","journal-title":"Ann Rheum Dis"}],"container-title":["Digestive and Liver Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S159086582400882X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S159086582400882X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,28]],"date-time":"2025-07-28T11:23:59Z","timestamp":1753701839000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S159086582400882X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":36,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["S159086582400882X"],"URL":"https:\/\/doi.org\/10.1016\/j.dld.2024.07.018","relation":{},"ISSN":["1590-8658"],"issn-type":[{"value":"1590-8658","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Small molecules for inflammatory bowel disease and the risk of infection and malignancy: A systematic review and meta-Analysis","name":"articletitle","label":"Article Title"},{"value":"Digestive and Liver Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.dld.2024.07.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}